

Antonio Palumbo

List of Publications by Citations

Source: <https://exaly.com/author-pdf/3239926/antonio-palumbo-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

267
papers

26,393
citations

64
h-index

161
g-index

270
ext. papers

30,732
ext. citations

5.9
avg, IF

6.43
L-index

#	Paper	IF	Citations
267	International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. <i>Lancet Oncology, The</i> , 2014 , 15, e538-48	21.7	2253
266	Multiple myeloma. <i>New England Journal of Medicine</i> , 2011 , 364, 1046-60	59.2	1724
265	Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. <i>New England Journal of Medicine</i> , 2008 , 359, 906-17	59.2	1580
264	International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. <i>Lancet Oncology, The</i> , 2016 , 17, e328-e346	21.7	1155
263	Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2863-9	2.2	976
262	Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. <i>New England Journal of Medicine</i> , 2016 , 375, 754-66	59.2	965
261	Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , 2015 , 373, 621-31	59.2	935
260	Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. <i>New England Journal of Medicine</i> , 2015 , 372, 142-52	59.2	928
259	Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. <i>Lancet, The</i> , 2006 , 367, 825-31	40	691
258	Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. <i>New England Journal of Medicine</i> , 2016 , 374, 1621-34	59.2	684
257	Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. <i>Blood</i> , 2011 , 117, 4691-5	2.2	681
256	Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. <i>Leukemia</i> , 2008 , 22, 414-23	10.7	654
255	Continuous lenalidomide treatment for newly diagnosed multiple myeloma. <i>New England Journal of Medicine</i> , 2012 , 366, 1759-69	59.2	578
254	Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. <i>Lancet Oncology, The</i> , 2016 , 17, 27-38	21.7	576
253	Autologous transplantation and maintenance therapy in multiple myeloma. <i>New England Journal of Medicine</i> , 2014 , 371, 895-905	59.2	539
252	Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. <i>Blood</i> , 2016 , 127, 2955-62	2.2	463
251	Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. <i>Blood</i> , 2015 , 125, 2068-74	2.2	426

250	IMWG consensus on risk stratification in multiple myeloma. <i>Leukemia</i> , 2014 , 28, 269-77	10.7	387
249	Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. <i>Journal of Clinical Oncology</i> , 2010 , 28, 5101-9	2.2	368
248	Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3279-3289	2.2	361
247	Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. <i>Journal of Clinical Oncology</i> , 2010 , 28, 2259-66	2.2	352
246	Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. <i>Blood</i> , 2010 , 116, 4745-53	2.2	325
245	Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. <i>Blood</i> , 2008 , 112, 3107-14	2.2	293
244	Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study. <i>Lancet Haematology</i> , 2016 , 3, e196-204	14.6	270
243	Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). <i>Blood</i> , 2011 , 118, 4519-29	2.2	267
242	Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement. <i>Journal of Clinical Oncology</i> , 2015 , 33, 657-64	2.2	262
241	Thalidomide for treatment of multiple myeloma: 10 years later. <i>Blood</i> , 2008 , 111, 3968-77	2.2	260
240	International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. <i>Journal of Clinical Oncology</i> , 2014 , 32, 587-600	2.2	255
239	Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. <i>Blood</i> , 2011 , 117, 4696-700	2.2	252
238	European Myeloma Network guidelines for the management of multiple myeloma-related complications. <i>Haematologica</i> , 2015 , 100, 1254-66	6.6	222
237	Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. <i>Lancet Oncology</i> , 2015 , 16, 1617-29	21.7	218
236	Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders. <i>Leukemia</i> , 2014 , 28, 1299-307	10.7	213
235	Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. <i>Blood</i> , 2011 , 117, 3025-31	2.2	207
234	Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. <i>Lancet Oncology</i> , 2014 , 15, 333-42	21.7	206
233	International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1544-57	2.2	204

232	Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study. <i>Lancet Oncology, The</i> , 2013 , 14, 1129-1140	21.7	189
231	Management of treatment-emergent peripheral neuropathy in multiple myeloma. <i>Leukemia</i> , 2012 , 26, 595-608	10.7	189
230	Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM. <i>Blood</i> , 2016 , 127, 2833-40	2.2	182
229	New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG). <i>Leukemia</i> , 2014 , 28, 525-42	10.7	179
228	Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. <i>Journal of Clinical Oncology</i> , 2014 , 32, 634-40	2.2	171
227	Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group. <i>Leukemia</i> , 2016 , 30, 1005-17	10.7	159
226	Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma. <i>Blood</i> , 2016 , 127, 681-95	2.2	154
225	Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials. <i>Haematologica</i> , 2013 , 98, 980-7	6.6	151
224	IMWG consensus on maintenance therapy in multiple myeloma. <i>Blood</i> , 2012 , 119, 3003-15	2.2	150
223	International Myeloma Working Group recommendations for global myeloma care. <i>Leukemia</i> , 2014 , 28, 981-92	10.7	132
222	Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2019 , 393, 253-264	40	131
221	Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study. <i>Blood</i> , 2014 , 124, 63-9	2.2	114
220	Survival and years of life lost in different age cohorts of patients with multiple myeloma. <i>Journal of Clinical Oncology</i> , 2010 , 28, 1599-605	2.2	113
219	Mutational activation of N- and K-ras oncogenes in plasma cell dyscrasias. <i>Blood</i> , 1993 , 81, 2708-2713	2.2	105
218	Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3459-66	2.2	104
217	Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth. <i>British Journal of Haematology</i> , 2017 , 178, 896-905	4.5	101
216	Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting. <i>Blood Cancer Journal</i> , 2018 , 8, 109	7	97
215	18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease. <i>Leukemia</i> , 2016 , 30, 417-22	10.7	96

214	Minimal Residual Disease Detection by Droplet Digital PCR in Multiple Myeloma, Mantle Cell Lymphoma, and Follicular Lymphoma: A Comparison with Real-Time PCR. <i>Journal of Molecular Diagnostics</i> , 2015 , 17, 652-60	5.1	92
213	Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma. <i>Blood</i> , 2016 , 128, 1174-80	2.2	86
212	Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma. <i>Blood</i> , 2016 , 128, 1821-1828	2.2	82
211	A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS). <i>Leukemia</i> , 2017 , 31, 107-114	10.7	81
210	Cancer-selective targeting of the NF- κ B survival pathway with GADD45/MKK7 inhibitors. <i>Cancer Cell</i> , 2014 , 26, 495-508	24.3	77
209	European perspective on multiple myeloma treatment strategies in 2014. <i>Oncologist</i> , 2014 , 19, 829-44	5.7	77
208	Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma. <i>Blood</i> , 2016 , 127, 1102-8	2.2	72
207	Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients. <i>Blood</i> , 2017 , 130, 2610-2618	2.2	69
206	Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics impact on survival. <i>Leukemia</i> , 2015 , 29, 689-95	10.7	68
205	Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives. <i>Leukemia</i> , 2016 , 30, 526-35	10.7	67
204	Second primary malignancies in multiple myeloma: an overview and IMWG consensus. <i>Annals of Oncology</i> , 2017 , 28, 228-245	10.3	66
203	Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia. <i>Leukemia</i> , 2014 , 28, 222-5	10.7	63
202	Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials. <i>Haematologica</i> , 2013 , 98, 87-94	6.6	63
201	Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival. <i>Clinical Cancer Research</i> , 2011 , 17, 1253-63	12.9	58
200	Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3921-3930	2.2	58
199	Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma. <i>Blood</i> , 2015 , 125, 449-56	2.2	54
198	Proteomic characterization of circulating extracellular vesicles identifies novel serum myeloma associated markers. <i>Journal of Proteomics</i> , 2016 , 136, 89-98	3.9	52
197	Efficacy of carfilzomib lenalidomide dexamethasone (KRd) with or without transplantation in newly diagnosed myeloma according to risk status: Results from the FORTE trial.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 8002-8002	2.2	52

196	Management of older adults with multiple myeloma. <i>Blood Reviews</i> , 2013 , 27, 133-42	11.1	50
195	Proteomic characterization of human multiple myeloma bone marrow extracellular matrix. <i>Leukemia</i> , 2017 , 31, 2426-2434	10.7	49
194	Double Vs Single Autologous Stem Cell Transplantation After Bortezomib-Based Induction Regimens For Multiple Myeloma: An Integrated Analysis Of Patient-Level Data From Phase European III Studies. <i>Blood</i> , 2013 , 122, 767-767	2.2	48
193	Whole-exome sequencing of primary plasma cell leukemia discloses heterogeneous mutational patterns. <i>Oncotarget</i> , 2015 , 6, 17543-58	3.3	45
192	Circulating miRNA markers show promise as new prognosticators for multiple myeloma. <i>Leukemia</i> , 2014 , 28, 1922-6	10.7	44
191	Activated idiotype-reactive cells in suppressor/cytotoxic subpopulations of monoclonal gammopathies: correlation with diagnosis and disease status. <i>Blood</i> , 1988 , 72, 1064-1068	2.2	44
190	Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment. <i>Blood Cancer Journal</i> , 2017 , 7, e554	7	42
189	Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR. <i>Leukemia</i> , 2017 , 31, 1368-1374	10.7	41
188	Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma. <i>Blood Cancer Journal</i> , 2020 , 10, 17	7	39
187	Activated idiotype-reactive cells in suppressor/cytotoxic subpopulations of monoclonal gammopathies: correlation with diagnosis and disease status. <i>Blood</i> , 1988 , 72, 1064-1068	2.2	37
186	Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy. <i>Haematologica</i> , 2014 , 99, 1114-22	6.6	35
185	How to manage neutropenia in multiple myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2012 , 12, 5-11	2	33
184	Lenalidomide (LEN) maintenance (MNTC) after high-dose melphalan and autologous stem cell transplant (ASCT) in multiple myeloma (MM): A meta-analysis (MA) of overall survival (OS).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 8001-8001	2.2	32
183	Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015 , 15, 519-30	2	31
182	Randomized Clinical Trial Representativeness and Outcomes in Real-World Patients: Comparison of 6 Hallmark Randomized Clinical Trials of Relapsed/Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020 , 20, 8-17.e16	2	31
181	Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma. <i>Leukemia</i> , 2016 , 30, 1211-4	10.7	30
180	A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myeloma. <i>Leukemia</i> , 2016 , 30, 1320-6	10.7	30
179	Have drug combinations supplanted stem cell transplantation in myeloma?. <i>Blood</i> , 2012 , 120, 4692-8	2.2	30

178	Lenalidomide: a new therapy for multiple myeloma. <i>Cancer Treatment Reviews</i> , 2008 , 34, 283-91	14.4	30
177	Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study. <i>Leukemia</i> , 2018 , 32, 1803-1807	10.7	29
176	Venous and arterial thrombotic risks with thalidomide: evidence and practical guidance. <i>Therapeutic Advances in Drug Safety</i> , 2012 , 3, 255-66	3.5	29
175	Prolonged Duration of Therapy Is Associated With Improved Survival in Patients Treated for Relapsed/Refractory Multiple Myeloma in Routine Clinical Care in the United States. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018 , 18, 152-160	2	27
174	Clinical characteristics of patients with relapsed multiple myeloma. <i>Cancer Treatment Reviews</i> , 2015 , 41, 827-35	14.4	26
173	Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis. <i>Oncotarget</i> , 2017 , 8, 5924-5935	3.3	26
172	Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis. <i>Cancer</i> , 2019 , 125, 750-760	6.4	26
171	Safety and Efficacy of Daratumumab with Lenalidomide and Dexamethasone in Relapsed or Relapsed, Refractory Multiple Myeloma. <i>Blood</i> , 2014 , 124, 84-84	2.2	25
170	Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial. <i>Journal of Clinical Oncology</i> , 2020 , 38, 4030-4041	2.2	25
169	Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials. <i>Leukemia and Lymphoma</i> , 2016 , 57, 2833-2838	1.9	23
168	Tumor-Stroma Ratio is an independent predictor for overall survival and disease free survival in gastric cancer patients. <i>Journal of the Royal College of Surgeons of Edinburgh</i> , 2017 , 15, 329-335	2.5	22
167	Serial Echocardiographic Assessment of Patients (Pts) with Relapsed Multiple Myeloma (RMM) Receiving Carfilzomib and Dexamethasone (Kd) Vs Bortezomib and Dexamethasone (Vd): A Substudy of the Phase 3 Endeavor Trial (NCT01568866). <i>Blood</i> , 2015 , 126, 4250-4250	2.2	22
166	A Phase III Study Of ASCT Vs Cyclophosphamide-Lenalidomide-Dexamethasone and Lenalidomide-Prednisone Maintenance Vs Lenalidomide Alone In Newly Diagnosed Myeloma Patients. <i>Blood</i> , 2013 , 122, 763-763	2.2	20
165	Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial. <i>Haematologica</i> , 2020 , 105, 1937-1947	6.6	20
164	Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma. <i>Leukemia</i> , 2018 , 32, 979-985	10.7	19
163	Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2018 , 130, 27-35	7	17
162	Time to first disease progression, but not beta2-microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy. <i>Cancer</i> , 2007 , 110, 824-9	6.4	17
161	A Phase III Study to Determine the Efficacy and Safety of Lenalidomide in Combination with Melphalan and Prednisone (MPR) in Elderly Patients with Newly Diagnosed Multiple Myeloma.. <i>Blood</i> , 2009 , 114, 613-613	2.2	17

160	Strategy for the treatment of multiple myeloma utilizing monoclonal antibodies: A new era begins. <i>Leukemia and Lymphoma</i> , 2016 , 57, 537-56	1.9	16
159	Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial. <i>Journal of Hematology and Oncology</i> , 2019 , 12, 4	22.4	16
158	Phase II study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma; the Carthadex trial. <i>Haematologica</i> , 2019 , 104, 2265-2273	6.6	16
157	Once-weekly twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase I/II studies. <i>Haematologica</i> , 2019 , 104, 1640-1647	6.6	16
156	Real-world outcomes and factors impacting treatment choice in relapsed and/or refractory multiple myeloma (RRMM): a comparison of VRd, KRd, and IRd. <i>Expert Review of Hematology</i> , 2020 , 13, 421-433	2.8	16
155	Preliminary Results from a Phase 1b Study of TAK-079, an Investigational Anti-CD38 Monoclonal Antibody (mAb) in Patients with Relapsed/ Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2019 , 134, 140-140	2.2	16
154	A Phase III Study of Enoxaparin Versus Low-Dose Warfarin Versus Aspirin as Thromboprophylaxis for Patients with Newly Diagnosed Multiple Myeloma Treated up-Front with Thalidomide-Containing Regimens. <i>Blood</i> , 2008 , 112, 3017-3017	2.2	16
153	The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD). <i>Oncotarget</i> , 2016 , 7, 9666-79	3.3	16
152	Successful mobilization of PBSCs predicts favorable outcomes in multiple myeloma patients treated with novel agents and autologous transplantation. <i>Bone Marrow Transplantation</i> , 2015 , 50, 673-674	4.4	15
151	Optimizing Treatment for Elderly Patients With Newly Diagnosed Multiple Myeloma: A Personalized Approach. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3600-3604	2.2	15
150	Lenalidomide and low-dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: A comparison of two prospective trials. <i>American Journal of Hematology</i> , 2017 , 92, 244-250	7.1	14
149	Maintenance therapy for multiple myeloma. <i>Hematology/Oncology Clinics of North America</i> , 2014 , 28, 839-59	3.1	14
148	Diagnosis and therapy of multiple myeloma. <i>Korean Journal of Internal Medicine</i> , 2013 , 28, 263-73	2.5	14
147	Reduced Dose-Intensity Subcutaneous Bortezomib Plus Prednisone (VP) Or Plus Cyclophosphamide (VCP) Or Plus Melphalan (VMP) For Newly Diagnosed Multiple Myeloma Patients Older Than 75 Years Of Age. <i>Blood</i> , 2013 , 122, 539-539	2.2	13
146	A Simple Score, Based On Geriatric Assessment, Improves Prediction of Survival, and Risk Of Serious Adverse Events In Elderly Newly Diagnosed Multiple Myeloma Patients. <i>Blood</i> , 2013 , 122, 687-687 ²	2.2	13
145	Melphalan/prednisone/lenalidomide (MPR) versus high-dose melphalan and autologous transplantation (MEL200) plus lenalidomide maintenance or no maintenance in newly diagnosed multiple myeloma (MM) patients.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 8509-8509	2.2	13
144	First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials. <i>Haematologica</i> , 2020 , 105, 1074-1080	6.6	13
143	Carfilzomib and pomalidomide in patients with relapsed and/or refractory multiple myeloma with baseline risk factors. <i>Annals of Oncology</i> , 2015 , 26, 2247-56	10.3	12

142	Continued Overall Survival Benefit After 5 Years PFollow-up with Bortezomib-Melphalan-Prednisone (VMP) Versus Melphalan-Prednisone (MP) in Patients with Previously Untreated Multiple Myeloma, and No Increased Risk of Second Primary Malignancies: Final Results of the Phase 3 VISTA Trial. <i>Blood</i> , 2011 , 118, 476-476	2.2	12
141	Carfilzomib-lenalidomide-dexamethasone (KRd) vs carfilzomib-cyclophosphamide-dexamethasone (KCd) induction: Planned interim analysis of the randomized FORTE trial in newly diagnosed multiple myeloma (NDMM).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 8003-8003	2.2	12
140	Minimal residual disease (MRD) monitoring by multiparameter flow cytometry (MFC) in newly diagnosed transplant eligible multiple myeloma (MM) patients: Results from the EMN02/HO95 phase 3 trial.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 8011-8011	2.2	12
139	Bendamustine for the treatment of multiple myeloma in first-line and relapsed-refractory settings: a review of clinical trial data. <i>Leukemia and Lymphoma</i> , 2015 , 56, 559-67	1.9	11
138	A Phase III Study of Enoxaparin vs Aspirin vs Low-Dose Warfarin as Thromboprophylaxis for Newly Diagnosed Myeloma Patients Treated with Thalidomide Based-Regimens.. <i>Blood</i> , 2009 , 114, 492-492	2.2	11
137	A Randomized Phase 3 Trial Of Melphalan-Lenalidomide-Prednisone (MPR) Or Cyclophosphamide-Prednisone-Lenalidomide (CPR) Vs Lenalidomide Plus Dexamethasone (Rd) In Elderly Newly Diagnosed Multiple Myeloma Patients. <i>Blood</i> , 2013 , 122, 536-536	2.2	11
136	Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life. <i>Blood Cancer Journal</i> , 2021 , 11, 40	7	11
135	Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trials. <i>Critical Reviews in Oncology/Hematology</i> , 2018 , 132, 9-16	7	11
134	Novel investigational drugs active as single agents in multiple myeloma. <i>Expert Opinion on Investigational Drugs</i> , 2017 , 26, 699-711	5.9	10
133	Natural History of Multiple Myeloma Relapsing After Therapy with IMiDs and Bortezomib: A Multicenter International Myeloma Working Group Study.. <i>Blood</i> , 2009 , 114, 2878-2878	2.2	10
132	Overall Survival Benefit for Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance with Bortezomib-Thalidomide (VMPT-VT) Versus Bortezomib-Melphalan-Prednisone (VMP) in Newly Diagnosed Multiple Myeloma Patients. <i>Blood</i> , 2012 , 120, 200-200	2.2	10
131	Maintenance Therapy With Lenalidomide Significantly Improved Survival Of Yong Newly Diagnosed Multiple Myeloma Patients. <i>Blood</i> , 2013 , 122, 2089-2089	2.2	10
130	A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis. <i>Blood</i> , 2014 , 124, 35-35	2.2	10
129	Vantage 088: Vorinostat in Combination with Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma: Results of a Global, Randomized Phase 3 Trial. <i>Blood</i> , 2011 , 118, 811-811	2.2	9
128	A Phase 3 Study Evaluating the Efficacy and Safety of Lenalidomide (Len) Combined with Melphalan and Prednisone Followed by Continuous Lenalidomide Maintenance (MPR-R) in Patients (Pts) ≥5 Years (Yrs) with Newly Diagnosed Multiple Myeloma (NDMM): Updated Results for Pts Aged 65-75 Yrs Enrolled in MM-015. <i>Blood</i> , 2011 , 118, 475-475	2.2	8
127	Impact of Bortezomib Incorporated Into Autotransplantation On Outcomes of Myeloma Patients with High-Risk Cytogenetics: An Integrated Analysis of 1894 Patients Enrolled in Four European Phase 3 Studies. <i>Blood</i> , 2012 , 120, 749-749	2.2	8
126	Pomalidomide + Low-Dose Dexamethasone in Patients with Refractory or Relapsed and Refractory Multiple Myeloma and Renal Impairment: Analysis of Patients from the Phase 3b Stratus Trial (MM-010). <i>Blood</i> , 2014 , 124, 4755-4755	2.2	8
125	Efficacy and safety of ixazomib plus lenalidomide-dexamethasone (IRd) vs placebo-rd in patients (pts) with relapsed/refractory multiple myeloma (RRMM) by cytogenetic risk status in the global phase III Tourmaline-MM1 study.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 8018-8018	2.2	8

124	Novel treatment paradigm for elderly patients with multiple myeloma. <i>American Journal of Blood Research</i> , 2011 , 1, 190-204	1.6	8
123	Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, high-risk myeloma patients not eligible for transplant: a pooled analysis of two studies. <i>Haematologica</i> , 2021 , 106, 1079-1085	6.6	8
122	Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018 , 18, 533-540	2	7
121	Role of consolidation/maintenance therapy in multiple myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013 , 13 Suppl 2, S349-54	2	7
120	Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study. <i>Leukemia and Lymphoma</i> , 2017 , 58, 552-559	1.9	7
119	Bortezomib, Melphalan, Prednisone and Thalidomide (VMPT) Followed by Maintenance with Bortezomib and Thalidomide for Initial Treatment of Elderly Multiple Myeloma Patients.. <i>Blood</i> , 2009 , 114, 128-128	2.2	7
118	A Prospective, Randomized Study of Melphalan, Prednisone, Lenalidomide (MPR) versus Melphalan (200 Mg/M2) and Autologous Transplantation (Mel200) in Newly Diagnosed Myeloma Patients: An Interim Analysis.. <i>Blood</i> , 2009 , 114, 350-350	2.2	7
117	A Phase III Study of Enoxaparin Vs Aspirin as Thromboprophylaxis for Newly Diagnosed Myeloma Patients Treated with Lenalidomide-Based Regimen.. <i>Blood</i> , 2010 , 116, 1092-1092	2.2	7
116	Melphalan/Prednisone/Lenalidomide (MPR) Versus High-Dose Melphalan and Autologous Transplantation (MEL200) in Newly Diagnosed Multiple Myeloma (MM) Patients . <i>Blood</i> , 2011 , 118, 3069-3069	2.2	7
115	Global myeloma research clusters, output, and citations: a bibliometric mapping and clustering analysis. <i>PLoS ONE</i> , 2015 , 10, e0116966	3.7	7
114	Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018 , 144, 1357-1366	4.9	6
113	Stem cell transplantation in multiple myeloma and other plasma cell disorders (report from an EBMT preceptorship meeting). <i>Leukemia and Lymphoma</i> , 2016 , 57, 1256-68	1.9	6
112	Part II: role of maintenance therapy in transplant-ineligible patients. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013 , 11, 43-9	7.3	6
111	Bortezomib-Based Induction Treatments Improve Outcomes of Newly Diagnosed Multiple Myeloma Patients with High-Risk Cytogenetic Abnormalities. <i>Blood</i> , 2010 , 116, 781-781	2.2	6
110	A Phase II Study With Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) For Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2013 , 122, 685-685	2.2	6
109	Phase 2 Study of Carfilzomib, Thalidomide, and Low-Dose Dexamethasone As Induction/Consolidation in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma, the Carthadex Trial. <i>Blood</i> , 2016 , 128, 1141-1141	2.2	6
108	A Multicenter, Open Label Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (MM) Patients. <i>Blood</i> , 2016 , 128, 1145-1145	2.2	6
107	Second primary malignancies (SPM) in newly diagnosed myeloma (MM) patients treated with lenalidomide (Len): Meta-analysis of 6,383 individual patient data (IPD).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 8517-8517	2.2	6

106	Treatment of Newly Diagnosed Elderly Multiple Myeloma. <i>Cancer Treatment and Research</i> , 2016 , 169, 123-143	3.5	6
105	Defibrotide (DF), an Orally Bioavailable Modulator of Myeloma Tumor-Microenvironment Interactions: Molecular Sequelae and Clinical Implications.. <i>Blood</i> , 2006 , 108, 3523-3523	2.2	5
104	The Weekly Infusion of Bortezomib Reduces Peripheral Neuropathy.. <i>Blood</i> , 2009 , 114, 3887-3887	2.2	5
103	Carfilzomib Combined with Thalidomide and Dexamethasone (CARTHADEX) As Induction Treatment Prior to High-Dose Melphalan (HDM) in Newly Diagnosed Patients with Multiple Myeloma (MM). A Trial of the European Myeloma Network EMN. <i>Blood</i> , 2011 , 118, 633-633	2.2	5
102	Pomalidomide Cyclophosphamide and Prednisone (PCP) Treatment for Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2012 , 120, 446-446	2.2	5
101	Doublet Vs Triplet Lenalidomide-Containing Regimens in Newly Diagnosed Myeloma Patients, Younger or Older Than 75 Years: Subgroup Analysis of a Phase III Study. <i>Blood</i> , 2014 , 124, 2110-2110	2.2	5
100	Carfilzomib in Combination with Bendamustine and Dexamethasone (CbD) in Relapsed and/or Refractory Patients with Multiple Myeloma: The Phase I/II EMN09 Study. <i>Blood</i> , 2016 , 128, 3334-3334	2.2	5
99	Continuous treatment (CT) versus fixed duration of therapy (FDT) in newly diagnosed myeloma patients: PFS1, PFS2, OS endpoints.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 8515-8515	2.2	5
98	Twin randomized studies of daratumumab (DARA; D) plus standard of care (lenalidomide/dexamethasone or bortezomib/dexamethasone [DRd or DVd]) versus Rd or Vd alone in relapsed or refractory multiple myeloma (MM): 54767414MMY3003 (Pollux) and 54767414MMY3004 (Castor).. <i>Journal of Clinical Oncology</i> , 2015 , 33, TPS8609-TPS8609	2.2	5
97	Lenalidomide Maintenance with or without Prednisone in Newly Diagnosed Myeloma Patients: A Pooled Analysis. <i>Cancers</i> , 2019 , 11,	6.6	4
96	Have drug combinations supplanted stem cell transplantation in myeloma?. <i>Hematology American Society of Hematology Education Program</i> , 2012 , 2012, 335-341	3.1	4
95	Impact of FISH and Cytogenetics On Overall and Event Free Survival in Myeloma: An IMWG Analysis of 9,897 Patients.. <i>Blood</i> , 2009 , 114, 743-743	2.2	4
94	Optimal Treatment Sequencing In Multiple Myeloma: An Exploratory Modeling Approach. <i>Blood</i> , 2010 , 116, 3046-3046	2.2	4
93	Analysis of Second-Line Lenalidomide Following Initial Relapse in the MM-015 Trial. <i>Blood</i> , 2012 , 120, 944-944	2.2	4
92	Weekly Carfilzomib, Cyclophosphamide and Dexamethasone (wCCd) in Newly Diagnosed Multiple Myeloma Patients: A Phase I- II Study. <i>Blood</i> , 2014 , 124, 175-175	2.2	4
91	Cell-Free DNA for Minimal Residual Disease Monitoring in Multiple Myeloma Patients. <i>Blood</i> , 2014 , 124, 3423-3423	2.2	4
90	Weekly Carfilzomib, Cyclophosphamide and Dexamethasone (wCCyd) in Elderly Newly Diagnosed Multiple Myeloma Patients: Results of a Phase 2 Study. <i>Blood</i> , 2015 , 126, 1828-1828	2.2	4
89	Prognostic Impact of Minimal Residual Disease By ASO-RQ-PCR in Multiple Myeloma: A Pooled Analysis of 2 Phase III Studies in Patients Treated with Lenalidomide after Front-Line Therapy. <i>Blood</i> , 2016 , 128, 4409-4409	2.2	4

88	Two phase 3 studies of the oral proteasome inhibitor (PI) ixazomib for multiple myeloma (MM) in the maintenance setting: TOURMALINE-MM3, and -MM4.. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS8068-TPS8068	2.2	4
87	Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US. <i>Annals of Hematology</i> , 2021 , 100, 2325-2337	3	4
86	Histological growth patterns and molecular analysis of resected colorectal lung metastases. <i>Pathology Research and Practice</i> , 2021 , 222, 153414	3.4	4
85	Pseudopyloric Metaplasia Is Not Associated With the Development of Gastric Cancer. <i>American Journal of Gastroenterology</i> , 2021 , 116, 1859-1867	0.7	4
84	A Multicenter, Open Label Study of Oral Lenalidomide and Prednisone (RP) Followed by Oral Lenalidomide Melphalan and Prednisone (MPR) and Oral Lenalidomide Maintenance In Newly Diagnosed Elderly Multiple Myeloma Patients. <i>Blood</i> , 2010 , 116, 1940-1940	2.2	3
83	Melphalan, Prednisone and Lenalidomide Followed by Lenalidomide Maintenance Improves Health-Related Quality of Life (HRQoL), with Newly Diagnosed Multiple Myeloma (NDMM) Patients [65 Years Benefiting From Delays in Disease Progression. <i>Blood</i> , 2011 , 118, 3157-3157	2.2	3
82	A Phase I/II Study of Pomalidomide-Cyclophosphamide-Prednisone (PCP) in Patients with Multiple Myeloma Relapsed/Refractory to Lenalidomide. <i>Blood</i> , 2011 , 118, 632-632	2.2	3
81	PFS2 In Elderly Patients With Newly Diagnosed Multiple Myeloma (NDMM): Results From The MM-015 Study. <i>Blood</i> , 2013 , 122, 405-405	2.2	3
80	Circulating Mir-130a in Multiple Myeloma and Extramedullary Myeloma Patients. <i>Blood</i> , 2014 , 124, 2043-2043	2.0	3
79	Autologous Transplantation Versus Cyclophosphamide-Lenalidomide-Prednisone Followed By Lenalidomide-Prednisone Versus Lenalidomide Maintenance in Multiple Myeloma: Long-Term Results of a Phase III Trial. <i>Blood</i> , 2015 , 126, 392-392	2.2	3
78	Monoclonal antibodies for treating multiple myeloma - a new era, new safety considerations?. <i>Expert Opinion on Drug Safety</i> , 2016 , 15, 1295-300	4.1	3
77	A prospective observational study to assess clinical decision-making, prognosis, quality of life and satisfaction with care in patients with relapsed/refractory multiple myeloma: the CLARITY study protocol. <i>Health and Quality of Life Outcomes</i> , 2018 , 16, 127	3	3
76	Sustained disease control in transplant-ineligible patients: the role of continuous therapy. <i>Leukemia Research</i> , 2012 , 36 Suppl 1, S19-26	2.7	2
75	Have drug combinations supplanted stem cell transplantation in myeloma?. <i>Hematology American Society of Hematology Education Program</i> , 2012 , 2012, 335-41	3.1	2
74	Neuropathy in Multiple Myeloma Patients Treated with Bortezomib: A Multicenter Experience.. <i>Blood</i> , 2007 , 110, 4823-4823	2.2	2
73	Bortezomib Plus MelphalanPrednisone Continues to Demonstrate a Survival Benefit Vs MelphalanPrednisone in the Phase III VISTA Trial in Previously Untreated Multiple Myeloma After 3 YearsFollow-up and Extensive Subsequent Therapy Use.. <i>Blood</i> , 2009 , 114, 3859-3859	2.2	2
72	Correlation Between Clinical Outcome and Disease Kinetics by Quantitative PCR in Myeloma Patients Following Post-Transplant Consolidation with Bortezomib, Thalidomide and Dexamethasone.. <i>Blood</i> , 2009 , 114, 960-960	2.2	2
71	A Phase III Study to Compare Melphalan, Prednisone, Lenalidomide (MPR) Versus Melphalan 200 Mg/m2 and Autologous Transplantation (MEL200) In Newly Diagnosed Multiple Myeloma Patients. <i>Blood</i> , 2010 , 116, 3573-3573	2.2	2

70	Long-Term Follow up of a Comparison of Non-Myeloablative Allografting with Autografting for Newly Diagnosed Myeloma. <i>Blood</i> , 2010 , 116, 525-525	2.2	2
69	Melphalan, Prednisone and Lenalidomide Followed by Lenalidomide Maintenance Displays Treatment Characteristics Favourable to Global Quality of Life in Newly Diagnosed Multiple Myeloma (NDMM) Patients ≥5 Years,. <i>Blood</i> , 2011 , 118, 3988-3988	2.2	2
68	Second Primary Malignancies in Newly Diagnosed Multiple Myeloma Patients Treated with Lenalidomide: Analysis of Pooled Data in 2459 Patients. <i>Blood</i> , 2011 , 118, 996-996	2.2	2
67	Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) for Newly Diagnosed Multiple Myeloma (MM) Patients. <i>Blood</i> , 2012 , 120, 730-730	2.2	2
66	The Presence of FDG PET/CT Focal, Not Osteolytic, Lesion(s) Identifies a Sub-Group of Patients with Smoldering Multiple Myeloma with High-Risk of Progression into Symptomatic Disease. <i>Blood</i> , 2014 , 124, 3371-3371	2.2	2
65	In Multiple Myeloma, Minimal Residual Disease (MRD) Is an Early Predictor of Progression and Is Modulated By Maintenance Therapy with Lenalidomide. <i>Blood</i> , 2014 , 124, 3394-3394	2.2	2
64	Mutational activation of N- and K-ras oncogenes in plasma cell dyscrasias. <i>Blood</i> , 1993 , 81, 2708-2713	2.2	2
63	Stem Cell Transplantation in Multiple Myeloma. <i>Current Cancer Drug Targets</i> , 2017 , 17, 769-781	2.8	2
62	Curative and Prophylactic Surgery of Young-onset Colorectal Cancer in Inherited Syndromes: A 15-Year Monocentric Retrospective Experience. <i>Anticancer Research</i> , 2019 , 39, 3131-3136	2.3	1
61	Autologous Transplantation in Elderly Multiple Myeloma Patients: Is the Procedure Cost Effective?. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 1705-6	4.7	1
60	Optimizing multiple myeloma treatment: conclusions. <i>Leukemia Research</i> , 2012 , 36 Suppl 1, S44-5	2.7	1
59	Clinical Outcomes According to Genomic Abnormalities in 566 Newly Diagnosed Multiple Myeloma Patients Treated with Bortezomib-Based Regimens.. <i>Blood</i> , 2009 , 114, 1868-1868	2.2	1
58	Sequential Approach with Bortezomib as Induction Before Autologous Transplantation, Followed by Lenalidomide as Consolidation-Maintenance in Untreated Multiple Myeloma Patients.. <i>Blood</i> , 2009 , 114, 3419-3419	2.2	1
57	Analysis of Transcriptome, Mirnome and Genomic Profiles in Association with Clinical Outcome in a Prospective Series of Primary Plasma Cell Leukemia. <i>Blood</i> , 2012 , 120, 3938-3938	2.2	1
56	Lenalidomide and Low Dose Dexamethasone As First Line Therapy for Newly Diagnosed Patients with Primary Plasma Cell Leukemia. <i>Blood</i> , 2012 , 120, 729-729	2.2	1
55	Next-Generation Sequencing and Real-Time Quantitative PCR for Minimal Residual Disease (MRD) Detection Using the Immunoglobulin Heavy Chain Variable Region: A Methodical Comparison in Acute Lymphoblastic Leukemia (ALL), Mantle Cell Lymphoma (MCL) and Multiple Myeloma (MM). <i>Blood</i> , 2012 , 120, 788-788	2.2	1
54	Circulating Mir-16 and Mir-25 As New Prognosticators For Multiple Myeloma. <i>Blood</i> , 2013 , 122, 1853-1853	2.2	1
53	Bendamustine, Low-Dose Dexamethasone, and Lenalidomide (BdL) For The Treatment Of Patients With Relapsed Multiple Myeloma Confirms Very Promising Results In a Phase I/II Study. <i>Blood</i> , 2013 , 122, 3212-3212	2.2	1

52	Improved Igh-Based MRD Detection By Using Droplet Digital PCR: a Comparison With Real Time Quantitative PCR In MCL and MM. <i>Blood</i> , 2013 , 122, 4290-4290	2.2	1
51	Dose Escalation Phase 2 Trial of Carfilzomib Combined with Thalidomide and Low-Dose Dexamethason in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma. a Trial of the European Myeloma Network. <i>Blood</i> , 2014 , 124, 2118-2118	2.2	1
50	Prospective Molecular Monitoring of Minimal Residual Disease after Non-Myeloablative Allografting in Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2014 , 124, 44-44	2.2	1
49	Safety and Efficacy in the Stratus (MM-010) Trial, a Single-Arm Phase 3b Study Evaluating Pomalidomide + Low-Dose Dexamethasone in Patients with Refractory or Relapsed and Refractory Multiple Myeloma. <i>Blood</i> , 2014 , 124, 80-80	2.2	1
48	Efficacy of Melflufen, a Peptidase Targeted Therapy, and Dexamethasone in an Ongoing Open-Label Phase 2a Study in Patients with Relapsed and Relapsed-Refractory Multiple Myeloma (RRMM) Including an Initial Report on Progression Free Survival. <i>Blood</i> , 2015 , 126, 3029-3029	2.2	1
47	Updated efficacy data and MRD analysis according to risk status in newly diagnosed myeloma patients treated with carfilzomib + lenalidomide or cyclophosphamide (FORTE trial).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 8009-8009	2.2	1
46	Analysis of Final Data from the Multinational, Non-Interventional, Observational Emmos Study (NCT01241396) in Patients (Pts) with Multiple Myeloma (MM) in Real-World Clinical Practice. <i>Blood</i> , 2015 , 126, 3034-3034	2.2	1
45	Minimal Residual Disease Detection By Multiparametric Flow Cytometry in Newly Diagnosed Multiple Myeloma Patients: A Preliminary Analysis of the EMN02/HO95 MM Study. <i>Blood</i> , 2015 , 126, 1760-1760	2.2	1
44	Flowcytometric Minimal Residual Disease Assessment in the EMN-02/HOVON-95 MM Trial: Used Methods and a Comparison of Their Sensitivity. <i>Blood</i> , 2016 , 128, 2072-2072	2.2	1
43	Minimal Residual Disease Monitoring During Maintenance In Multiple Myeloma Patients. <i>Blood</i> , 2013 , 122, 3126-3126	2.2	1
42	Carfilzomib Combined With Thalidomide and Low-dose Dexamethasone for Remission Induction and Consolidation in Newly Diagnosed Transplant Eligible Patients With Multiple Myeloma: 8 vs 4 Induction Cycles; the Carthadex Trial. <i>HemaSphere</i> , 2020 , 4, e370	0.3	1
41	Case report: skin injury after contact with a red spine starfish, <i>Protoreaster lincki</i> . <i>Contact Dermatitis</i> , 2018 , 78, 95-96	2.7	0
40	Immunotherapy: the next step in the treatment of myeloma. <i>Lancet Haematology,the</i> , 2015 , 2, e504-5	14.6	0
39	The Binding of CD38 Therapeutics to Red Blood Cells and Platelets Subverts Depletion of Target Cells. <i>Blood</i> , 2019 , 134, 3136-3136	2.2	0
38	Carfilzomib, bendamustine, and dexamethasone in patients with advanced multiple myeloma: The EMN09 phase 1/2 study of the European Myeloma Network. <i>Cancer</i> , 2021 , 127, 3413-3421	6.4	0
37	IH2 INHIBITION ENHANCES PROTEASOME INHIBITOR RESPONSIVENESS IN HEMATOLOGICAL MALIGNANCIES. <i>Hematological Oncology</i> , 2019 , 37, 515-515	1.3	
36	Frail Patients with Newly Diagnosed Multiple Myeloma 2018 , 539-549		
35	Latest advances in the management of elderly patients with multiple myeloma. <i>International Journal of Hematologic Oncology</i> , 2013 , 2, 431-434	1	

34	A new combination for advanced multiple myeloma. <i>Lancet Oncology, The</i> , 2011 , 12, 207-8	21.7
33	Impact of Early Consolidation with Bortezomib, Thalidomide and Dexamethasone on Molecularly-Detectable Disease in MM Patients in CR or VGPR Following Autologous Transplantation: Uncommon Achievement of Molecular Remission Despite Evidence of Tumor Load Reduction by Real Time PCR.. <i>Blood</i> , 2006 , 108, 3100-3100	2.2
32	Bortezomib and Plasma Cell Leukemia.. <i>Blood</i> , 2006 , 108, 3546-3546	2.2
31	Immunoglobulin (Ig) Repertoire in Multiple Myeloma: High Frequency of Recurrent Aminoacid Substitutions in the FR2 and CDR2.. <i>Blood</i> , 2006 , 108, 3413-3413	2.2
30	Risk Stratification in Newly Diagnosed Transplant Ineligible Multiple Myeloma 2018 , 37-58	
29	The Combination of Frailty and ISS Scores Identifies a Simple Prognostic Index for Overall Survival in Elderly Patients Treated with Novel Agents-Based Induction Therapy. <i>Blood</i> , 2014 , 124, 4740-4740	2.2
28	Outcomes for Older Patients in Stratus (MM-010), a Single-Arm, and Phase 3b Study of Pomalidomide + Low-Dose Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma. <i>Blood</i> , 2014 , 124, 4770-4770	2.2
27	Proteomic Characterization of the Multiple Myeloma Bone Marrow Extracellular Matrix. <i>Blood</i> , 2014 , 124, 2051-2051	2.2
26	Virtual Karyotype Reconstruction By SNPs Array of Newly Diagnosed Multiple Myeloma (MM) Patients Enrolled in the EMN02 Clinical Trial. <i>Blood</i> , 2014 , 124, 2033-2033	2.2
25	Multicolor Flowcytometry Analysis of Hematopoietic Stem and Progenitor Cells Subsets Among Basal and Mobilized Peripheral CD34+ Cells. <i>Blood</i> , 2014 , 124, 5117-5117	2.2
24	Proteomic Characterization of Circulating Extracellular Vesicles Identifies Novel Serum Myeloma Associated Markers. <i>Blood</i> , 2015 , 126, 1814-1814	2.2
23	Significant Survival Improvement with Maintenance in Patients Achieving a Complete Response: Pooled Analysis of 4 Italian Phase III Trials in Newly Diagnosed Multiple Myeloma Patients. <i>Blood</i> , 2015 , 126, 1974-1974	2.2
22	Impact of Complete Response on Survival with Either Autologous Stem Cell Transplantation or Conventional Chemotherapy: Results of a Pooled Analysis of 5 Phase III Trials in Newly Diagnosed Multiple Myeloma Patients. <i>Blood</i> , 2015 , 126, 927-927	2.2
21	Adverse event (AE) management in patients (pts) with relapsed and refractory multiple myeloma (RRMM) taking pomalidomide (POM) plus low dose-dexamethasone (LoDEX): A pooled analysis from 3 clinical trials.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 8031-8031	2.2
20	Prolonged Follow-up Confirmed a Role for Upfront Tandem Auto-Allo Transplant in Multiple Myeloma Also in the Era of New Drugs. <i>Blood</i> , 2016 , 128, 3469-3469	2.2
19	An Integrated Analysis of Cardio-Vascular Adverse Events of Carfilzomib, Cyclophosphamide and Dexamethasone in Elderly Newly Diagnosed Myeloma Patients Enrolled in 3 Phase I/II Trials. <i>Blood</i> , 2016 , 128, 3336-3336	2.2
18	Impact of Treatment Intensification According to Patient Prognosis: A Pooled Analysis of 3 Randomized Phase III Trials. <i>Blood</i> , 2016 , 128, 995-995	2.2
17	Hevylite and Freelite Tests in Newly Diagnosed Multiple Myeloma: Clinical Utility and Correlations with Clinical Features. <i>Blood</i> , 2016 , 128, 5625-5625	2.2

- 16 Prognostic Implication of Somatic Mutations By Next Generation Sequencing: An Analysis From the Mmrf Compass Study in Newly Diagnosed Multiple Myeloma Patients. *Blood*, **2016**, 128, 2079-2079 2.2
- 15 Bortezomib as Front-Line Therapy in Primary Plasma Cell Leukemia. *Blood*, **2008**, 112, 2784-2784 2.2
- 14 Lenalidomide Plus Dexamethasone Versus Lenalidomide Plus Melphalan and Prednisone: A Case-Control Study in Newly Diagnosed Elderly Myeloma Patients.. *Blood*, **2009**, 114, 2877-2877 2.2
- 13 Central Nervous System and Intracranial Myeloma: a Retrospective Italian Multicenter Study.. *Blood*, **2009**, 114, 1882-1882 2.2
- 12 High Expression of mRNA and Gene Amplification of Met In Myeloma Plasma Cells Characterize a More Aggressive Disease. *Blood*, **2010**, 116, 1898-1898 2.2
- 11 IGH Repertoire Analysis In Multiple Myeloma (MM): Lack of Intra-Disease Homology and Occasional Clustering with Sequences of Other B-Cell Neoplasms Sharing Identical Geographical Origin. *Blood*, **2010**, 116, 2951-2951 2.2
- 10 Does Heparin Have An Anti-Myeloma Effect? An Analysis On Individual Data From Three Randomized Studies of GIMEMA, Nordic and Turkish Myeloma Study Groups,. *Blood*, **2011**, 118, 3970-3970² 2.2
- 9 Evaluation of Atypical Low Energy Fractures in Patients Affected by Multiple Myeloma Treated with Bisphosphonates. *Blood*, **2011**, 118, 5134-5134 2.2
- 8 Differences in Patterns of Treatment and Outcome Among Patients with Relapsed Refractory Myeloma From United States, Europe and Asia,. *Blood*, **2011**, 118, 3989-3989 2.2
- 7 Prioritizing Content in Continuing Hematologic Oncology Education: A Survey of 51 Clinical Investigators. *Blood*, **2012**, 120, 4270-4270 2.2
- 6 miRNA in Serum and Bone Marrow Plasma Cells From Multiple Myeloma Patients.. *Blood*, **2012**, 120, 2921-2921 2.2
- 5 A Phase I/II Study of Bendamustine, Low-Dose Dexamethasone, and Lenalidomide (BdL) for the Treatment of Patients with Relapsed Multiple Myeloma. *Blood*, **2012**, 120, 1851-1851 2.2
- 4 Novel Agents and Autologous Stem Cell Transplantation Improve Survival of Multiple Myeloma Patients with Ages 65-70 Years: A Multicenter Retrospective Collaborative Study Between Japanese Society of Myeloma and European Myeloma Network. *Blood*, **2012**, 120, 5030-5030 2.2
- 3 Bendamustine As Salvage Therapy in Multiple Myeloma: A Retrospective, Multicenter Study From the Italian Compassionate Use Program in 78 Heavily Pre-Treated Patients.. *Blood*, **2012**, 120, 2971-2971^{2,2} 2.2
- 2 High Rates of Prolonged Molecular Remissions After Tandem Autologous-Nonmyeloablative Allografting in Newly Diagnosed Myeloma. *Blood*, **2012**, 120, 4204-4204 2.2
- 1 Lenalidomide (LEN)-melphalan-prednisone induction followed by LEN maintenance (MPR-R) in newly diagnosed multiple myeloma (NDMM) elderly patients (Pts) with moderate renal impairment (RI): MM-015 trial post-hoc analysis.. *Journal of Clinical Oncology*, **2013**, 31, 8544-8544 2.2